623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy in Low Grade Lymphoma


Jae H Park, Eric S. Winer, Scott F. Huntington, et al.

The chemotherapy-free combination of vemurafenib plus obinutuzumab induced a CR rate of 100% with high MRD negativity (96%) in patients with hairy cell leukemia (HCL) in the frontline setting. According to the authors, this is a promising targeted therapeutic approach for HCL. In most patients, normalization of cytopenia was observed after the 4-week lead-in of vemurafenib. There were no cases of febrile neutropenia and there was no evidence of significant T-cell immunosuppression during the course of therapy.


Tycel Phillips, Abraham Avigdor, Ronit Gurion, et al.

In patients with R / R-MZL, parsaclisib monotherapy resulted in a rapid and durable clinical response, generally good tolerability with a manageable safety profile. The authors suggest that parsaclisib could be a potential treatment option for R / R MZL.



Julio C. Chavez, Neta Goldschmidt, Felipe Samaniego, et al.

U2 had improved efficacy in patients with R / R-MZL and was highly active compared to a previous cohort of MZL patients treated with umbra mono in this study. With the U2 combination, there was a relatively low incidence of immune-mediated toxicities and AEs-related discontinuations.



Daobin Zhou, Jie Jin, Zheng-zheng Fu, et al.

In this short-term follow-up, orelabrutinib demonstrated significant efficacy in the treatment of R/R WM patients with a favorable safety and tolerability profile with limited side effects. According to the study authors, orelabrutinib has the potential to be a promising treatment option for WM patients.



Zrinka Sertić, Marko Lucijanic, Sandra Bašić-Kinda, et al.

It is known that patients with haematological diseases have poorer serological response rates to SARS-CoV-2 vaccines. The study results suggest that patients benefit from receiving both vaccine doses with no significant difference between vaccine types. Patients in active treatment with non-Hodgkin’s lymphoma without prior HSCT who received anti-CD20 mAb seem to be more likely to be seronegative after receiving both doses



Giulia Benevolo, Simone Ferrero, Nicoletta Villivà, et al.

The novel BRB combination as a second-line therapy has strong anti-tumor activity and is an effective and well-tolerated salvage treatment for RR-WM patients. This is demonstrated by an absolute increase in the PFS rate compared to historical controls (30-month PFS of 79%) and by high clinical response rates with an ORR (CR + VGPR + PR) of 82% (95% CI 66-92). MRD monitoring demonstrates the promising efficacy of BRB therapy in eliminating residual disease.